Zura Bio Analyst Price Targets - Benzinga

Zura Bio Ltd

ZURANASDAQ

Trade with Public

Trade with Public

$4.27

0.7119.94%

最終更新: Oct 28, 7:34 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

© 2026 Benzinga | All Rights Reserved

Zura Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zura Bio (ZURA).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$14Upside to Avg. PT+241.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$15→$22
Aug 12, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$15→$20
Jul 8, 2026	William Blair	Matt Phipps	Initiate	Outperform	—
Jul 1, 2026	Wedbush	Martin Fan	Maintained	Outperform	$15
Mar 23, 2026	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$10→$11
Mar 20, 2026	Oppenheimer	Justin Kim	PT Cut	Outperform	$16→$15
Feb 9, 2026	Wedbush	Martin Fan	Initiate	Outperform	$15
Nov 14, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
Nov 13, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$18
Sep 30, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
Aug 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Neutral	$3→$2
Aug 15, 2025	Oppenheimer	Justin Kim	PT Cut	Outperform	$17→$16
Aug 15, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$10
May 9, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$19→$17
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$5→$3
Mar 26, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$20→$19
Mar 26, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$15
Mar 26, 2025	Chardan Capital	Matthew Barcus	PT Cut	Buy	$12→$10
Dec 24, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$5
Dec 11, 2024	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	—

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22

Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20

Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Zura Bio with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Zura Bio (NASDAQ:ZURA) with a Outperform rating.

Benzinga Newsdesk

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.

Vandana Singh

PRO
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target

Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ:ZURA) with a Outperform and maintains $15 price target.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15

Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $15.

Benzinga Newsdesk